RESUMEN
OBJECTIVE: We aimed at investigating the prognostic significance of a novel immune marker, PIV and PILE score (a score composite from PIV, LDH and ECOG PS), in patients with HCC in a single center. PATIENTS AND METHODS: 120 patients who met the criteria were included. PIV and PILE at the time of diagnosis were computed retrospectively. For PIV, the median value of 286.15 was taken as the cut-off. While <286.15 was considered low, ≥286.15 was considered high PIV. The PILE score included PIV (< median vs. ≥ median), lactate dehydrogenase level (Asunto(s)
Carcinoma Hepatocelular
, Neoplasias Hepáticas
, Humanos
, Carcinoma Hepatocelular/diagnóstico
, Neoplasias Hepáticas/diagnóstico
, Pronóstico
, Estudios Retrospectivos
, Estudios Prospectivos